MTIP is the largest Pan-European growth equity investor purely focused on the healthtech sector, supporting companies that revolutionize global healthcare whilst generating top quartile returns to their investors. They invest in the most innovative healthtech companies that bring efficiency on healthcare accessibility, affordability, availability as well as quality. MTIP has a proven ability to invest across Europe with investments so far in 11 different European jurisdictions as well as internationally (e.g. USA, Israel), with a portfolio that includes Oviva, Trialbee and Intelligencia. MTIP’s purpose is to empower innovation that improves lives by accelerating the adoption of digital technologies in healthcare. They do this across digital health products, tech-enabled healthcare services as well as connected medical devices. As a leading impact investor, MTIP actively engages with their portfolio companies on ESG topics, and believes social responsibility is critical for long-term and sustainable value creation. Thus, the Swiss-based growth equity firm is proud to be SFDR Art.9 compliant as of MTIP Fund II onwards characterized as one of the first “dark green“ funds with their products targeting sustainable investments.
Our Members
Membership Options
European Healthcare Investor Association is a not-for-profit organisation answerable to its members in the annual general meeting. Our members are investors, current and former board members and senior managers of portfolio companies and advisors to the healthcare private equity community.
Investor Members
Investment funds active in healthcare comprising private equity, infrastructure, sovereign funds, foundations, real estate investors and family offices that meet the following criteria:
- more than €200m AUM
- two or more current or former healthcare portfolio companies or assets
- two or more nominated healthcare-focused investment professionals
Strategic Partners
Advisors active in the healthcare sector who support the Association with content and events
Non-investor Members
Other corporate entities that are neither Investor Members nor Strategic Partners.
Individual Members
Individual personal members comprising current or past board members or senior managers of healthcare companies or those with an interest in the sector.
Investor Members
Strategic Partners
Non-investor Members
Individual Members
Membership Benefits
Events and Networking
Invitations to exclusive dinners, breakfast seminars, networking drinks and report launches including:
- Investors in Healthcare Gala Dinner in London (during Jefferies)
- Women in Healthcare Investing networking events
- Investors in Healthcare drinks in San Francisco (during JP Morgan)
- Healthcare Services & Real Estate Dinner in London (during HBI)
- Healthcare Investing in Germany Networking Dinner in Dusseldorf (during Medica)
- Investors in Healthcare drinks in Amsterdam (during HLTH)
- European Healthcare & Life Sciences Investor Symposium in Frankfurt, Paris and London
- Healthcare Investing Networking Dinner in Milan (during CPHI)
Discounts to industry events including:
- Complimentary tickets for Investor Members to McDermott’s HPE Europe Conference London (value £695 per ticket)
- Complimentary tickets to Basel HealthTech Conference
- Discount to SuperReturn International Berlin (£1,200 per ticket)
- Discount to HLTH Europe Amsterdam
Opportunity to partner with EHIA on events with marketing support provided
Content and Community
Access to exclusive Member-only Webinars and On-Demand content including:
- Meet Your Members
- In Discussion with McKinsey
- Legal Insight with McDermott Will & Emery
Monthly newsletter containing:
- Member-only content
- Industry event calendar
- Latest transactions, with advisors and valuations
- Sector appointments
Complimentary Enterprise subscription to Investors in Healthcare, providing sector focussed news, data and analysis (value £1,495 p.a.)
Industry engagement, sector news through web site, e newsletters and LinkedIn: 7,000+ followers
Promotion of your brand and investment activities to the EHIA community
Membership includes access for an extensive number of team members per organisation (discretionary)
Find out More
To find out more about EHIA, download our credentials deck which provides some background on the Association, our current members, and member benefits.
Investor Members
Apposite Capital solely focuses on healthcare. It works closely with management teams, providing operational support and strategic guidance as much as capital to together build market-leading companies. It invests in high potential commercial-stage companies across Europe, with each investment tailored to each company’s needs and with a view to all types of financing structures (minority, growth, buyout, buyin, etc). Apposite typically seeks to invest £10-20 million over the life of each investment but an initial investment can be £5 million or less.
Ardian is a world-leading private investment house majority owned by its employees. They manage or advise $100bn across Europe, the Americas, Asia and Middle East, on behalf of governments, institutions, pension funds and high-net-worth investors. They are an entrepreneurial business, focused on supporting talented management teams to build sustainable, growing companies. They are committed to sharing their success as widely as possible – with investors, with employees in the companies they support and with society at large.
Since their founding, BC Partners have always believed that the best professionals, businesses, and brands are equal parts inspiring and credible. They have deliberately built a business that attracts people and partners who balance these traits. Their investment professionals are world class in what they do while creating a culture of humanity, honesty, transparency, and community. With over thirty years of investing across sectors and geographies, and strategies, they have truly deep and proprietary relationships.
capiton AG is an owner-managed private equity investor with a current fund volume of €1.3bn under management and a strong track record of over 20 years of investing in profitable companies in the DACH region. Currently investing out of their sixth fund, capiton’s key sectors are pharmaceuticals, medical and industrial technology and responsible consumption.
Established in 1981, CVC is a world leader in private equity and credit with $109.1 billion of assets under management, $160.3 billion of funds committed and a global network of 23 local offices: 15 across Europe and the Americas and eight in the Asia Pacific region. CVC is majority owned by its employees and led by its Managing Partners. CVC’s private equity platform manages $82 billion of assets and comprises four strategies: Europe/Americas; Asia; Strategic Opportunities; and Growth Partners, each of which benefits from CVC’s global platform. CVC’s ability to bring to bear the full extent of its global resources on any situation gives it a competitive advantage when sourcing new investment opportunities and when creating value during CVC’s ownership period.
Eurazeo is a leading global investment group, with a diversified portfolio of €32.5 billion in assets under management, including €23.4 billion from third parties, invested in over 530 companies. With its considerable Private Equity, real estate, private debt and fund of funds expertise, Eurazeo accompanies companies of all sizes, supporting their development through the commitment of its nearly 360 professionals and by offering deep sector expertise, a gateway to global markets, and a responsible and stable foothold for transformational growth. Its solid institutional and family shareholder base, robust financial structure free of structural debt, and flexible investment horizon enable Eurazeo to support its companies over the long term.
Five Arrows is the alternative assets arm of Rothschild & Co and has more than €23 billion AuM with offices in Paris, London, New York, Los Angeles, San Francisco and Luxembourg. With over €9 billion of assets under management, the corporate private equity business of Five Arrows is focused on investing in companies with highly defensible market positions; strong management teams; business models with high visibility of organic unit volume growth and strong unit economics; and multiple operational levers that can be used to unlock latent value. Sectors are limited to data and software, technology‑enabled business services and healthcare.
Gilde Healthcare is a specialized European healthcare investment firm. It manages €2.6 billion across its dedicated healthcare private equity and venture capital & growth funds. Gilde Healthcare has a track-record of superior returns spanning over 20 years. The firm employs 30 dedicated healthcare investment professionals with deep sector expertise across its offices in The Netherlands, Germany, and the US. The latest 500M Gilde Healthcare Private Equity Fund IV targets lower mid-market companies in North-Western Europe. Its portfolio includes successful investments in CRO/CDMO, Pharma, MedTech, Health IT and Care Providers. Recent PE investments include SDS Swiss Dental Solutions AG, a leading Swiss provider of ceramic dental implants, Essange Reagents, a Dutch developer and manufacturer of highly specialized IVD reagents, DETAX GmbH, a German producer of high end medical materials, Diener and Koscher&Wuertz, together forming a German CDMO group for precision surgical instruments, Ace Pharmaceuticals, a leading Dutch specialty pharma company focusing on medical need product and KLIFO, a Danish drug development consultancy. Through its investments, Gilde Healthcare actively contributes to its investment philosophy that enables Better Care at Lower Cost.
Gimv is a European investment company listed on Euronext Brussels with €2 billion AUM. With 60 portfolio companies currently under management, Gimv’s five platforms are: Consumer, Healthcare, Life Sciences, Smart Industries and Sustainable Cities. Through its Healthcare platform, Gimv is investing in care & patient providers, in leading B2B service & software companies in the healthcare sector and in healthcare products. The Life Sciences platform focuses on venture capital investments in pre-revenue R&D-driven companies that positively impact human health.
Goodgrower is a specialised healthcare investment firm with over €1bn of assets under management. Since 2007, they have backed numerous healthcare businesses and entrepreneurs worldwide. Their international team makes growth and buyout investments in healthcare businesses in Europe and the US, with tickets up to €30m. Goodgrower invests in subsectors like outsourced pharma services, medtech, healthcare IT, diagnostics, outpatient care/specialty clinics, consumer healthcare and animal health. They do not invest in pharma and biotech. Their portfolio also includes the second largest private hospital group in Spain (Vithas). Goodgrower is backed and entirely funded by the Gallardo Family, founders and main shareholders of pharmaceutical company Almirall.
H.I.G. Capital is a leading global alternative investment firm with $43 billion of equity capital under management with a focus on the small cap and mid cap segments of the market. H.I.G. Private Equity funds focus on leveraged buyouts and recapitalizations, including corporate divestitures and take-private transactions, typically in partnership with existing management in small and mid-sized companies that can benefit from H.I.G.’s in-house operating professionals and expertise. H.I.G. has invested in and managed more than 300 companies worldwide since its founding in 1993, with combined sales in excess of $30 billion. H.I.G. has offices in the U.S. and affiliate offices in Europe and Latin America.
ICG provides flexible capital solutions to help companies develop and grow. They are a leading global alternative asset manager with over 30 years’ history, managing c.$75bn of assets and investing across the capital structure. Their partnership capital funds, including €8bn flagship strategy and €1bn mid-market strategy support management teams, entrepreneurs, family owners and other financial investors with investments of between €50m and €1.5bn, with flexibility to invest across equity, preferred and debt instruments. Investing between $20m to $75m, the ICG Life Sciences team is focussed on investing in high quality management teams to develop innovative therapeutics to transform people’s live and deliver meaningful societal impact to patients and their families. ICG is listed on the London Stock Exchange (ticker symbol: ICP
Livingbridge is a mid-market private equity firm with offices in the UK, the US and Australia, which invests in fast-growing companies valued up to £300m. The team has backed growing companies for more than 20 years and achieved success with over 160 investments, turning many into household names, both in the UK and abroad. Livingbridge applies the entrepreneurial mindset that supports its own business to understand the people behind growing companies in four fast-moving markets: Services, Technology, Consumer and Healthcare & Education.
Morrison is one of the world’s longest-standing, highest-performing infrastructure investors. Founded in 1988, Morrison invests globally in private and listed infrastructure on behalf of institutional investors and sovereign wealth funds. Its team manages over USD 22bn in consolidated assets (as at 30 Sep 2023). Morrison’s purpose is to invest wisely in ideas that matter. Its people believe the best investments serve an enduring societal need. The Morrison team applies a specialist investment approach, refined over multiple decades and economic cycles, to invest in infrastructure for the modern economy. It has one of the largest specialist infrastructure teams, with over 180 professionals operating across seven global offices. Its people operate as a global firm with a local approach, adopting a one-team ethos, making its global expertise available to every investor, business and local community. For more information, visit https://morrisonglobal.com/ & LinkedIn.
Mubadala is a sovereign investor managing a $284bn portfolio of assets and investments in the United Arab Emirates and abroad, generating sustainable financial returns for its shareholder, the Government of Abu Dhabi. Mubadala’s diverse portfolio spans six continents with interests across multiple sectors and asset classes, including Life Sciences. Mubadala’s Life Sciences team pursues healthcare private equity investments globally, with a geographic focus on North America, Europe, and Asia. While the team looks at all areas of the healthcare ecosystem, its direct investments to date have focused on outsourced pharma services, healthcare IT, medical technology, and life science tools & diagnostics.
As a leading European private equity investor, Nordic Capital helps to grow stronger sustainable companies. With deep sector knowledge and long experience, they drive transformative growth. Nordic Capital is an active, engaged owner that works in close collaboration with portfolio companies, accelerating growth and often identifying truly transformative angles. Their goal is to use operational experience, capital and business acumen to create strong, sustainable businesses that will thrive in the long term.
Novo Holdings A/S, a private limited liability company fully owned by the Novo Nordisk Foundation, is the holding company in the Novo Group, and responsible for managing the Foundation’s assets.
Besides being the major shareholder in the Novo Group companies Novo Nordisk A/S, Novozymes A/S and NNIT A/S, Novo Holdings provides seed and venture capital to development stage companies and takes significant ownership positions in well-established companies within life science, as well as manages a broad portfolio of financial assets.
PAI Partners is a pre-eminent private equity firm investing in market-leading companies across Europe and North America. It manages c. €26 billion of dedicated buyout funds and, since 1994, has completed over 100 investments in 12 countries, representing over €70 billion in transaction value. For more than two decades, PAI has supported a high-quality portfolio of healthcare businesses, leading consolidation of fragmented markets and accelerating organic growth by leveraging its Consumer playbook into Healthcare and capitalising on the rise of outsourcing. The PAI team has successfully completed 11 deals across multiple healthcare sub-sectors: pharma, healthcare services, medtech and diagnostics. This includes Atos Medical, Cerba Healthcare, DomusVi, ELITech, Theramex and Veonet.
Partners Group is a leading global private markets firm. Since its establishment in 1996, the firm has invested USD 210 billion in private equity, private real estate, private debt, and private infrastructure on behalf of its clients worldwide. Partners Group aims to generate superior returns by capitalizing on thematic growth trends, transforming attractive businesses and assets into market leaders. The firm is committed to responsible investing, striving to create sustainable returns with a lasting, positive impact on all its stakeholders. With USD 147 billion in assets under management, Partners Group offers an innovative range of tailor-made client solutions to institutional investors, sovereign wealth funds, family offices and private individuals globally.
The Riverside Company is a global private investment firm focused on driving growth for companies at the smaller end of the middle market in Europe, North America and Australia. With approximately $13 billion in assets under management, Riverside has completed more than 1,000 investments since its founding in 1988. Healthcare investing is one of Riverside’s most active specializations, with more than 200 deals completed in the space. The firm’s current portfolio, inclusive of add-ons, features more than 65 healthcare company investments. In Europe, the latest Riverside Europe Fund targets control buyouts of companies with up to €30 million EBITDA. Visit https://www.riversidecompany.com/industries/healthcare/ to learn more about Riverside’s Healthcare specialization.
.
Schroders Capital is a leading global private markets investor and part of Schroders Group. With over US$90 billion assets under management, the firm manages a range of investment strategies, including private equity and private debt. The private equity team of Schroders Capital invests through direct/co-investments, secondaries and primary investments across buyout, growth and venture capital with a focus on fundamental value generation through transformational change. Healthcare is a key sector for Schroders Capital with a dedicated investment team and total sector investments of >€2.5bn, including >€1bn direct and co-investments into >80 companies.
Founded in 2017, Telemos invests in private European businesses, with the aim of building great companies for the long term. Funded by family capital, they combine the flexibility and nimble decision-making of a family office with the active ownership and professionalism of private equity. Telemos looks to deploy €50m-€200m of equity per investment, with an aim of building a concentrated portfolio of majority stakes in companies, supported by an active partnership approach. They seek to invest in high-performing, cash-flow generative and well-managed businesses with the potential for sustainable growth through international expansion, add-on acquisitions and/or operational improvements. Telemos has a pan European geographical focus including both Western as well as Central and Eastern Europe.
Triton is an investment firm that invests primarily in German-speaking and the Nordic countries, the Benelux region, France, Italy, Spain and the United Kingdom in the industrials, business service, consumer and health sectors. They focus on companies with the potential to create sustainable, long-term value through changing economic cycles and we work closely with management to achieve that. Our investments are supported by three core principles: Thoughtful investing; Consistent strategy and Responsibility.
Verlinvest is an international, family-backed investment company focused on backing businesses that are driving consumer revolutions. Established in 1995, with offices in Europe, the US and Asia, Verlinvest has over €2bn in assets under management and focuses on the FMCG, health, consumer technology and lifestyle categories, investing across three strategies: Platform, Growth & Venture. In healthcare, Verlinvest looks for companies that put patient-consumers at the heart of everything they do. In Europe, this typically means investing €40m to €250m for control or co-control positions in businesses that are professionalising and consolidating their respective industries with the potential to build platforms.
Strategic Partners
McKinsey & Company is a global management consulting firm committed to helping organizations create Change that Matters. In more than 130 cities and 65 countries, our teams help clients across the private, public and social sectors shape bold strategies and transform the way they work, embed technology where it unlocks value, and build capabilities to sustain the change. Not just any change, but Change that Matters –for their organizations, their people, and in turn society at large.
J.P. Morgan is a leader in investment banking, commercial banking, financial transaction processing and asset management. We serve millions of customers, predominantly in the U.S., and many of the world’s most prominent corporate, institutional and government clients globally. Through continued investments, business initiatives and philanthropic commitments, we aim to help our employees, customers, clients and communities grow and thrive.
McDermott, Will & Emery lawyers work seamlessly across practices, industries and geographies, having 20+ locations and more than 1,400 lawyers globally. Their health private equity team collaborates with those at the forefront of health and life sciences innovation to foster the unique partnerships and business ventures that are transforming healthcare. As the industry’s top ranked law firm for health and life sciences ventures, they have advised on hundreds of healthcare deals covering the full range of health and life sciences services, life sciences tools and pharma services, medtech, hospital and behavioural health services, inpatient/outpatient services, laboratory services, information technology, business processing outsourcing and more. Their London and European teams are consistently recognised by all of the major rankings and directories including Legal 500 and Chambers & Partners, as well as their US practice which has been named “Health Law Firm of the Year”
three times by Chambers USA. In 2023, McDermott was ranked #1 in healthcare private equity by deal volume. Clients choose McDermott teams for their unique combined expertise in health and life sciences, cross border practice and regulatory and transactional and finance teams.
The Marwood Group is a healthcare-focused advisory and consulting firm headquartered in New York City with offices in Washington, D.C. and London. With a deep understanding of the influence policy, politics and market dynamics have on reimbursement, regulation, and business performance, Marwood Group supports their client’s investment decisions in assets across Europe and the United States.
Marwood provides investors and operators with policy, regulatory, funding and reimbursement analysis, assessing the risk and opportunities that result from government action on the national or local level. A multilingual European team brings years of relevant healthcare expertise to every engagement.
Knight Frank is one of the world’s leading independent real estate consultancies, with a healthcare team consistently ranked as the UK’s no.1 healthcare property consultancy. Advising annually on £12 billion assets, Knight Frank’s expertise extends across the full spectrum of healthcare subsectors, including care homes, specialist care & mental health, independent hospitals, primary care surgeries, children’s nurseries and specialist education. As valuer to the majority of the UK’s major operators, funds, investors and lenders in the healthcare space, Knight Frank healthcare is now extending its presence in Europe, drawing upon a multi-service solution that adds value at every stage.
Compass Executives is an award-winning UK based executive search consultancy working with global, European and UK investors. From traditional equity and VC funding through to REIT’s and infrastructure entrants, they provide bespoke human capital solutions for board, leadership, finance and corporate functions. Their specialism and focus is the health, social care, education and life sciences sector spaces. Compass Executives facilitate the placements of elite talent and have a substantive track record across funding cycles where their introductions have yielded significant value add on exit for their investment partners.
RSM Ebner Stolz is the leading multidisciplinary mid-market advisory and audit firm in Germany. They work closely with their clients to gain a thorough understanding of their business and provide customized solutions. Their teams of experts help clients manage transformational measures, navigate the complex regulatory landscape and promote sustainable growth. Ebner Stolz joined the RSM network in October 2023.
Healthcare, Pharma and MedTech represent key sectors and the advisory practice in transactions and corporate finance has grown substantially over the past years. They have deep expertise both of the deals environment as well as recent regulatory and commercial market trends with which they navigate clients through a fast-paced and dynamic healthcare and medical industry environment. Working with many of the renowned healthcare private equity investors and players in the market, they support decision-makers throughout the entire investment lifecycle with corporate finance, financial, tax as well as legal and regulatory advisory services. RSM Ebner Stolz consultants follow a multidisciplinary approach by working as “one team” without boundaries to share key knowledge and information between disciplines. This way they cover a multitude of perspectives and add high value to each project.
Marsh’s HealthCare Practice helps clients define, design, and deliver solutions that meet the unique needs of providers and payers alike. With an in-depth understanding of today’s healthcare challenges, their extended team of insurance and healthcare professionals works with clients to define the organisation’s risk profile. Then they use the industry’s most powerful analytics to help you quantify risk and determine how much to mitigate, retain, or transfer.
Non-Investor Members
CMS lawyers work across sectors and borders in more than 40 countries worldwide to deliver advice to you wherever you operate. They see themselves as more than just legal advisers, but as business partners. Their focus is on helping you mitigate risk and benefit from innovation, enabling your business or organisation to thrive.
Bevan Brittan LLP is a market leader in the delivery of legal and regulatory services to the independent health and care market, winning the HealthInvestor “Legal Advisor- Transactional Award” for the last 3 years. Bevan Brittan have an exceptional, award-winning, multi-disciplinary team of 60+ partners and 250 lawyers who passionately and proactively advise health and social care investors and portfolio companies on the full range of operational and transactional matters across all of the major sub-markets of independent health and social care, as well as medtech and life sciences. Last year Bevan Brittan transacted over £30B of businesses/assets, including advising on some of the most important and high-value transactions across elderly and specialist care, children’s services, senior living, private hospitals, diagnostics, med tech, pharmaceuticals, digital and primary care.
Harris Williams is a global investment bank specializing in M&A advisory services. Clients worldwide rely on them to help unlock value in their business and turn ambitious goals into reality. They approach every engagement with boundless collaboration, pooling expertise and relationships across industries and geographies to uncover the unique story of each company. With deep sector knowledge, their Healthcare & Life Sciences Group helps investors and company leaders capitalize on the strong demographic tailwinds and the fast-paced innovation that is driving growing demand and new M&A opportunities in the industry. For over 30 years, clients have trusted Harris Williams to think strategically, execute precisely, and deliver premium outcomes through M&A.
Houlihan Lokey is the trusted advisor to more top decision-makers than any other independent global investment bank. They help their clients achieve superior outcomes by providing thoughtful, caring advice while acting with honour and integrity. They are strategic in their approach to growth and are committed to creating lasting value for their shareholders. Houlihan Lokey’s Healthcare Group has earned a reputation for providing superior service and achieving outstanding results in M&A advisory, capital-raising, restructuring, and financial and valuation advisory services. They provide in-depth knowledge, proven transaction experience, and an exceptional level of service to their clients. The team has extensive relationships with public and private strategic and financial sponsors, and the clients they serve span a broad range of sectors.
JSR LifeSciences, LLC, along with its affiliate companies, Crown Bioscience, KBI Biopharma, Inc., Selexis S.A. and MBL, bring together deep understanding of human disease, expertise in drug discovery and development and manufacturing into a single, integrated framework that creates value for their customers. JSR supports the drug discovery and development needs of their partners by delivering reliable, innovative, and technically differentiated services and products essential for advancing their customers’ assets. From de-risking molecule selection and accelerating drug development timelines, to increasing clinical success rates, JSR LifeSciences is committed to guiding their customers’ innovative science along the path to deliver precision medicine.
Hill Dickinson LLP is a leading and award-winning international commercial law firm with 950 people, including over 200 partners and legal directors. From offices in the UK, mainland Europe and Asia, it delivers advice and strategic guidance spanning the full legal spectrum. Hill Dickinson has specialist teams in healthcare, social care, pharma, medtech and life sciences, providing strategic advice and support to clients ranging from multinational companies, major corporations, UK plcs, insurance companies, banks and financial institutions, private equity and venture capital investors, public sector organisations, private individuals, and professional bodies. Their clients include start-ups, scale-ups, new entrants as well as major established businesses across private hospitals, clinics, primary care, mental health & social care, medtech, biotech, life science and pharma. The firm acts as a trusted adviser on public and private capital market fundraising, secured lending and borrowing, mergers, acquisitions, corporate structuring, real estate development, regulatory advisory and due diligence, commercial contracts through to all forms of commercial litigation and arbitration and judicial reviews.
Alcon is the world leader in eye care, dedicated to helping people see brilliantly. With a 70-plus-year heritage, they are the largest eye care device company in the world – with complementary businesses in Surgical and Vision Care. The business is built on a solid foundation of market-leading eye care expertise and deep, long-standing relationships with eye care professionals. Alcon is leading in eye care innovation and is well-positioned for growth in an expanding global marketplace. They have a long history of industry firsts, based on deep capabilities in materials science, surface chemistry and optics. A strong pipeline includes more than 100 projects in process and more than 1,400 associates worldwide researching and developing treatments for vision conditions and eye diseases.
Latham & Watkins is a global law firm with more than 3,000 lawyers in its offices located in Asia, Europe, the Middle East and the United States. The firm delivers innovative solutions to complex legal and business challenges around the world. Their healthcare and life sciences lawyers advise clients on market-shaping transactions, high-stakes litigation and trials, and sophisticated regulatory matters. The cross-disciplinary healthcare and life sciences private equity team advises the world’s leading private equity firms and brings together strength in fund formation, private equity finance, M&A, and capital markets to deliver seamless and responsive support to private equity clients at every stage of a fund’s lifecycle. The firm has broad experience in advising major private equity players and their portfolio companies on transactions across all relevant sub-sectors within the industry including pharma, medical technology, biotechnology, hospitals and other healthcare services providers and others. Many of their lawyers hold advanced scientific degrees and have served in senior positions as government regulators, C-Suite executives in leading healthcare and life sciences companies, as well as serving as primary outside counsel for key industry associations.
Portolano Cavallo combines in-depth knowledge of the Life Sciences and Healthcare sector, where they are a leading law firm in Italy, with sophisticated Private Equity and Venture Capital expertise, and with full-service capability. Thanks to this, they are uniquely positioned to support Private Equity and Venture Capital funds throughout the investment life cycle and portfolio management. Their expertise encompasses corporate, regulatory and compliance matters, intellectual property, data protection, cybersecurity, competition and consumer law, foreign direct investment (FDI) and more. 60% of their work is cross-border. Expertise in Life Sciences and Healthcare means that they work on all the legal and regulatory issues regarding pharmaceuticals, biotechnologies, medical devices, diagnostics, healthcare, digital health, food supplements, and more. As leaders in Digital, Media and Technology in Italy, Portolano is the go-to firm for complex and cutting-edge matters where technology and Life Sciences intersect. The firm offers innovative solutions to tackle critical business challenges. They are committed to diversity, and place a dedicated focus on sustainability.
Mansfield Advisors is a leading strategy consulting firm focussed on the healthcare, social care, education, life sciences, pharma and veterinary markets. They work for public and private companies and investors, helping them buy, sell and create value in businesses. The firm advises on corporate strategy and commercial due diligence by combining research, benchmarking, modelling and analysis with clinical, scientific and operational knowledge.
Mansfield was founded in 2013 by two former McKinsey consultants, Victor Chua and Adam Scott who have a team of consultants including scientists, medical doctors, dentists and vets, supported by Senior Advisors who are often former CEOs with direct operational expertise. Whilst based in London, Mansfield’s focus is European and their team is international, speaking 10 languages.
